These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 19865017)
1. Aminoglycosides--engineering important patient-centered outcomes with antibiotics. Noble DW Crit Care Med; 2009 Oct; 37(10):2855-6. PubMed ID: 19865017 [No Abstract] [Full Text] [Related]
2. Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Lipcsey M; Carlsson M; Larsson A; Algotsson L; Eriksson M; Lukinius A; Sjölin J Crit Care Med; 2009 Oct; 37(10):2782-90. PubMed ID: 19707126 [TBL] [Abstract][Full Text] [Related]
3. [Disorders of kidney function and acute kidney failure in newborn infants]. Burghard R; Leititis JU; Brandis M Monatsschr Kinderheilkd; 1987 Jan; 135(1):10-21. PubMed ID: 3561418 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacodynamics of tobramycin in the infant and the child]. Bégué P; Laplane R Nouv Presse Med; 1974 Apr; 3(0):64-6. PubMed ID: 4600777 [No Abstract] [Full Text] [Related]
7. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Santos JI; Swensen P; Glasgow LA Pediatrics; 1981 Jul; 68(1):50-4. PubMed ID: 7243509 [TBL] [Abstract][Full Text] [Related]
8. Errors associated with applying decision support by suggesting default doses for aminoglycosides. Eslami S; Abu-Hanna A; de Keizer NF; de Jonge E Drug Saf; 2006; 29(9):803-9. PubMed ID: 16944965 [TBL] [Abstract][Full Text] [Related]
9. Back to the future: using aminoglycosides again and how to dose them optimally. Drusano GL; Ambrose PG; Bhavnani SM; Bertino JS; Nafziger AN; Louie A Clin Infect Dis; 2007 Sep; 45(6):753-60. PubMed ID: 17712761 [TBL] [Abstract][Full Text] [Related]
10. Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 2. Peloquin C Antimicrob Agents Chemother; 2010 Jun; 54(6):2750-1; author reply 2752. PubMed ID: 20480959 [No Abstract] [Full Text] [Related]
11. [A study of the cochleo-vestibular tolerance of tobramycin in man. Preliminary study]. Brogard JM; Conraux C; Collard M; Jahn H; Lavillaureix J Nouv Presse Med; 1974 Apr; 3(0):75-9. PubMed ID: 4600182 [No Abstract] [Full Text] [Related]
12. Renal toxicity due to inhaled tobramycin in lung transplant recipients. Laporta R; Ussetti P; Carreño MC J Heart Lung Transplant; 2006 May; 25(5):608. PubMed ID: 16678043 [No Abstract] [Full Text] [Related]
13. Antibiotics and ERCP: in vitro activity of aminoglycosides when added to iodinated contrast agents. Jendrzejewski JW; McAnally T; Jones SR; Katon RM Gastroenterology; 1980 Apr; 78(4):745-8. PubMed ID: 7353761 [No Abstract] [Full Text] [Related]
14. [Urinary myelin bodies and the nephrotoxicity of aminoglycosides]. Coulon G; Saint-Hillier Y; Carbillet JP; Laroze M; Hory B; Perol C; Oppermann A Nephrologie; 1984; 5(3):107-14. PubMed ID: 6436721 [TBL] [Abstract][Full Text] [Related]
15. [Which are the factors of toxic and pharmacological risk implicated in occurrence of acute renal failure during the perioperative period?]. Cittanova ML Ann Fr Anesth Reanim; 2005 Feb; 24(2):167-76. PubMed ID: 15737503 [No Abstract] [Full Text] [Related]
16. [Drug dosage in renal failure -- traps and aids]. Aymanns C; Keller F Med Klin (Munich); 2004 Oct; 99(10):613-24; quiz 625. PubMed ID: 15490077 [No Abstract] [Full Text] [Related]
17. [Acute renal failure caused by tobramycin]. Tabernero Romo JM; Macias Nuñez JF; Bondia Roman A; Sanchez Sanchez R; De Castro Del Pozo S Rev Clin Esp; 1976 Oct; 143(1):93-6. PubMed ID: 1005801 [No Abstract] [Full Text] [Related]
18. [Nephrotoxicity of aminoglycosides: risk factors (2)]. Arellano Abia F Med Clin (Barc); 1989 Oct; 93(12):471-5. PubMed ID: 2691772 [No Abstract] [Full Text] [Related]
19. Tobramycin in the medical intensive care unit. Ellinoy BR; Matsuda K; Nguyen TM Crit Care Med; 2005 Apr; 33(4):919. PubMed ID: 15818142 [No Abstract] [Full Text] [Related]
20. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. Pai MP; Rodvold KA Diagn Microbiol Infect Dis; 2014 Feb; 78(2):178-87. PubMed ID: 24268292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]